Equifax saw a positive improvement to its Relative Strength (RS) Rating on Friday, rising from 69 to 74.
When To Sell Stocks To Lock In Profits And Minimize Losses
IBD's proprietary rating measures market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the last 52 weeks stacks up against all the other stocks in our database.
Decades of market research reveals that the market's biggest winners often have an 80 or higher RS Rating in the early stages of their moves. See if Equifax can continue to rebound and hit that benchmark.
Equifax is not currently offering a proper buying opportunity. See if the stock goes on to form a promising consolidation that could spark a new run.
The company reported 2% EPS growth last quarter, while sales growth came in at 4%.
Equifax holds the No. 23 rank among its peers in the Financial Services-Specialty industry group. X Financial ADR, Tradeweb Markets and Marex Group are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
IBD Stock Rating Upgrades: Rising Relative Strength
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
